NeuroDerm (NDRM) Design of ND0612 Phase III iNDiGO Efficacy Trial Accepted by European Medicines Agency
Tweet Send to a Friend
NeuroDerm Ltd. (NASDAQ: NDRM) today announced that it has received a Scientific Advice Letter from the Scientific Advice Working Party ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE